New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:14 EDTDO, NE, ESV, ZGNX, NNVC, KORS, AMGN, DHI, PIKE, HK, HIMX, TKMR, RIG, INSMOn The Fly: Pre-market Movers
HIGHER: Pike (PIKE), up 48% after signing a definitive merger agreement under which Court Square Capital Partners and the company's chairman and CEO will acquire the company in a transaction in which each of the company's shareholders will receive $12.00 per share cash... Amgen (AMGN), up 3.5% after the company reported its Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival... NanoViricides (NNVC), up 9% after starting anti-ebola virus drug development program. Tekmira (TKMR), which also has an anti-Ebola treatment under development, is up 8.8%... D.R. Horton (DHI), up 2% after Barron's says analyst see the stock reaching $31.00 per share in a year... Himax (HIMX), up 4% after upgraded at Lake Street. LOWER: Michael Kors (KORS), down 3.8% after Q2 guidance miss expectations, company says its sees FY15 gross margins to be down 50 bps... Zogenix (ZGNX), down 7% after resignation of Chief Commercial Officer Scott Shively... Transocean (RIG), down 2.3% after downgraded to Sell at Deutsche Bank. The firm also downgraded Diamond Offshore (DO) and Ensco (ESV) to Sell this morning and lowered its rating on Noble Corp. (NE) to Hold from Buy... Halcon Resources (HK), down 4.8% after downgraded at Morgan Stanley... Insmed (INSM), down 27% after announcing that, following discussions with European regulatory authorities, it intends to file by the end of 2014 a Marketing Authorization Application with the EMA for Arikayce.
News For KORS;RIG;PIKE;NNVC;TKMR;DHI;ZGNX;HIMX;AMGN;INSM;HK;DO;ESV;NE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 28, 2015
07:34 EDTAMGNJefferies sees entry point for Aegerion, upgrades to Buy
Subscribe for More Information
07:05 EDTDHID.R. Horton says well-positioned to finish FY strong, have even stronger FY16
07:05 EDTDHID.R. Horton reports Q3 EPS 60c, consensus 50c
Subscribe for More Information
July 27, 2015
06:20 EDTRIG, NE, DOU.S. oil firms preparing for extended job cuts, WSJ reports
U.S. energy companies intend to cut more jobs, sell more assets, and engage in more financial maneuvers to deal with the recent drop in U.S. crude-oil prices to below $50 a barrel, the Wall Street Journal reports. Companies have started to warn that more layoffs will come, particularly Halliburton (HAL) and Baker Hughes (BHI), who disclosed last week that they had cut 27,000 jobs between them, the report says. Job cuts for the industry are beginning to extend to engineers and scientists, the report adds. Publicly traded companies in oil industry include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Other publicly traded companies in the space include Baker Hughes (BHI), Diamond Offshore (DO), Halliburton (HAL), Nabors Industries (NBR), Noble Corp. (NE), Rowan Companies (RDC), Schlumberger (SLB), Transocean (RIG) and Weatherford (WFT). Reference Link
July 24, 2015
15:00 EDTAMGNBroader label for PCSK9 drug positive for Regeneron, Amgen, says Deutsche Bank
Subscribe for More Information
12:44 EDTAMGNAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTAMGNFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
July 23, 2015
17:15 EDTZGNXIntegrated Core Strategies reports 5.6% passive stake in Zogenix
10:00 EDTKORSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTAMGNAmgen submits NDA for Kyprolis in relapsed multiple myeloma
Amgen submitted a supplemental New Drug Application to the FDA for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Kyprolis currently has accelerated approval in the U.S. for the treatment of patients with relapsed multiple myeloma as a monotherapy. The sNDA is based on data from the global Phase 3 ENDEAVOR trial in which relapsed multiple myeloma patients treated with Kyprolis and dexamethasone lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade.
08:48 EDTKORSMichael Kors downgraded to Neutral from Buy at Buckingham
Subscribe for More Information
July 21, 2015
12:47 EDTAMGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:49 EDTAMGNNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
07:12 EDTAMGNAmgen's Repatha granted marketing authorization by EC
Amgen announced that the European Commission, or EC, has granted marketing authorization for Repatha, or evolocumab, the first proprotein convertase subtilisin/kexin type 9, or PCSK9, inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
July 20, 2015
08:41 EDTTKMRTekmira to change corporate name to Arbutus Biopharma
Subscribe for More Information
July 16, 2015
19:07 EDTESVConocoPhillips provides notice of termination for ENSCO DS-9 drillship contract
Subscribe for More Information
19:04 EDTESVOn The Fly: After Hours Movers
Subscribe for More Information
16:05 EDTAMGNAmgen announces Phase 2 trial results evaluating Blincyto
Subscribe for More Information
10:00 EDTKORSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:21 EDTKORSMichael Kors downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Michael Kors to Mixed following checks that indicate U.S. Department Store sales are below goals and feedback that popularity is waning due to over distribution.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use